Fisher Asset Management LLC Has $19.86 Million Stock Position in Scholar Rock Holding Corporation $SRRK

Fisher Asset Management LLC boosted its holdings in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 29.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 533,176 shares of the company’s stock after buying an additional 120,765 shares during the period. Fisher Asset Management LLC owned approximately 0.55% of Scholar Rock worth $19,855,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Moody Aldrich Partners LLC raised its stake in Scholar Rock by 53.5% during the 3rd quarter. Moody Aldrich Partners LLC now owns 101,742 shares of the company’s stock valued at $3,789,000 after purchasing an additional 35,481 shares during the last quarter. Norges Bank bought a new position in shares of Scholar Rock during the 2nd quarter worth about $41,628,000. Voya Investment Management LLC raised its position in shares of Scholar Rock by 18.1% during the third quarter. Voya Investment Management LLC now owns 443,155 shares of the company’s stock valued at $16,503,000 after buying an additional 67,839 shares during the last quarter. Nan Fung Trinity HK Ltd. bought a new stake in shares of Scholar Rock in the third quarter valued at about $1,402,000. Finally, Ensign Peak Advisors Inc lifted its stake in shares of Scholar Rock by 78.8% in the second quarter. Ensign Peak Advisors Inc now owns 600,639 shares of the company’s stock valued at $21,275,000 after buying an additional 264,693 shares during the period. 91.08% of the stock is owned by institutional investors.

Key Scholar Rock News

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: BMO Capital Markets raised its price target from $50 to $70 and kept an “outperform” rating (~47.6% upside vs. the current price). BMO Raises PT to $70
• Positive Sentiment: Citigroup raised its target to $58 and maintained a “buy” rating (~22% upside). Citigroup Raises PT to $58
• Positive Sentiment: Piper Sandler raised its target to $58 and kept an “overweight” rating (similar ~22% upside). Piper Sandler PT Raise Street Insider
• Positive Sentiment: HC Wainwright reaffirmed a “buy” and a $58 target. HC Wainwright Reaffirmation TickerReport
• Positive Sentiment: Q4 results narrowly beat expectations — reported EPS (net loss) was ($0.76) vs. consensus (~$0.86), which analysts viewed positively relative to estimates. Earnings Release / Summary
• Neutral Sentiment: Full earnings and Q&A transcripts are now available (multiple outlets posted call transcripts), useful for digging into pipeline updates and management tone. Seeking Alpha Transcript InsiderMonkey Transcript
• Negative Sentiment: Despite the beat, the corrected press release clarifies net loss per share was $0.76 for Q4 vs. $0.61 a year earlier — an increase in the loss year‑over‑year, underscoring ongoing unprofitability. BusinessWire Correction

Wall Street Analyst Weigh In

SRRK has been the subject of several recent research reports. Wolfe Research assumed coverage on Scholar Rock in a report on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 price target for the company. Citigroup boosted their price objective on Scholar Rock from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday. Piper Sandler raised their target price on Scholar Rock from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday. UBS Group began coverage on shares of Scholar Rock in a report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price target on the stock. Finally, Truist Financial increased their price objective on shares of Scholar Rock from $44.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday. Four research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Scholar Rock currently has an average rating of “Buy” and an average target price of $54.14.

Scholar Rock Stock Performance

Shares of NASDAQ:SRRK opened at $47.43 on Thursday. The stock has a market capitalization of $4.84 billion, a price-to-earnings ratio of -13.83 and a beta of 0.70. The business’s fifty day moving average price is $45.32 and its two-hundred day moving average price is $39.14. Scholar Rock Holding Corporation has a fifty-two week low of $22.71 and a fifty-two week high of $49.82. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.30 and a quick ratio of 6.30.

Scholar Rock (NASDAQ:SRRK) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.10. During the same quarter in the prior year, the business posted ($0.64) earnings per share. As a group, analysts predict that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.

Insider Activity

In related news, insider Jing L. Marantz sold 4,157 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total transaction of $193,425.21. Following the completion of the sale, the insider directly owned 126,012 shares of the company’s stock, valued at $5,863,338.36. This trade represents a 3.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Caryn Parlavecchio sold 9,035 shares of Scholar Rock stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total value of $420,398.55. Following the completion of the transaction, the insider owned 169,087 shares of the company’s stock, valued at approximately $7,867,618.11. The trade was a 5.07% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 208,470 shares of company stock valued at $9,201,778 over the last three months. 13.30% of the stock is owned by corporate insiders.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).